Cellular Therapy Preempts Diabetic Nephropathy
Dr. H. David Humes, Professor of Internal Medicine
University of Michigan Medical Center
Department of Medicine Grand Rounds
April 24th, 2008, 8:30 – 9:30 AM
This year, special excitement surrounds the potential description of a means of using cells grown in culture to cure diabetes and its kidney consequences.
H. David Humes, MD graduated in 1973 from the medical school of the University of California, San Francisco, where he stayed to complete his internship and residency training in 1975. He spent a year as a Clinical Fellow in Nephrology at the Hospital of the University of Pennsylvania and then another year as a Research Fellow in the Laboratory of Kidney and Electrolyte Physiology at Peter Bent Brigham Hospital in Boston. He joined the faculty at Harvard Medical School as an Instructor in 1977 and departed in 1979 as an Assistant Professor of Medicine.
The University of Michigan recruited Dr. Humes as an Assistant Professor of Internal Medicine in 1979. Since joining the faculty of the Department of Internal Medicine, he has served many roles, including Director of the Nephrology Research Laboratories, Chief of the Nephrology Section at the VA Medical Center, Chief of the Medical Service at the VA Medical Center, Acting Chief of Staff at the VA Medical Center, and Associate Chair of the Department. He rose quickly through the faculty ranks and became a full Professor in 1986. Dr. Humes was appointed the John G. Searle Professor and Chair of the Department of Internal Medicine at the University of Michigan in 1996, a position he held until 2000.
Dr. Humes is a member of the editorial board of five scientific journals. He has published approximately 180 scientific papers and has edited numerous textbooks, including, and most recently, Kelley's Textbook of Internal Medicine. Additionally, he has 40 patents issued or pending.
He is an international authority in the areas of acute renal failure, stem cell biology, and tissue engineering and has received NIH funding for over twenty years. Recently, his laboratory received national and international attention for its work in the development of the bioartificial kidney. Dr. Humes has been elected to a number of prestigious honorary scientific societies, including Alpha Omega Alpha; Fellow, American College of Physicians; American Society of Clinical Investigation; Association of American Physicians; and Fellow, American Association for the Advancement of Science.
A number of highly acclaimed awards in Nephrology have been bestowed on him, including The President's Award from the National Kidney Foundation and the A.N. Richards Distinguished Achievement Award in Nephrology.
Dr. Humes is active in the for-profit sector, with involvement in several start-up companies. Most notably, he is the scientific founder, director, and chief science officer of RenaMed Biologics, Inc. (formerly Nephros Therapeutics, Inc.), a biotechnology company directed to bioartificial organs and cell- and drug-delivery devices, and he is the founder of Innovative BioTherapies, a company developing nanofabricated replacement organs utilizing stem cells.
Publications by Dr. David S. Humes
The Cutting Edge of Renal-Replacement Therapy
First human trial of bioartificial kidney shows promise
Bioartificial kidney under study at Medical College of Georgia
Recent Publications by Dr. Humes